+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Treatment of PNH Market by Treatment Type (Eculizumab, Pegcetacoplan, Ravulizumab), Mechanism of Action (C3 Inhibitor, C5 Inhibitor), Route of Administration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Treatment of PNH Market by Treatment Type (Eculizumab, Pegcetacoplan, Ravulizumab), Mechanism of Action (C3 Inhibitor, C5 Inhibitor), Route of Administration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Treatment of PNH Market by Treatment Type (Eculizumab, Pegcetacoplan, Ravulizumab), Mechanism of Action (C3 Inhibitor, C5 Inhibitor), Route of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6118408
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Paroxysmal nocturnal hemoglobinuria (PNH) represents a rare, acquired hematologic disorder characterized by uncontrolled complement activation that leads to hemolysis, bone marrow failure, and significant thrombotic events. The disruption in complement regulation on red blood cell surfaces gives rise to chronic anemia, fatigue, and life-threatening complications. Over the past two decades, targeted complement inhibitors have reshaped the therapeutic landscape, offering previously unattainable clinical benefits and improving patient outcomes.

Despite these advances, significant challenges persist. Clinicians and policy makers continue to navigate complex reimbursement pathways, variable patient responses, and logistical demands associated with intravenous biologics. Moreover, emerging therapies are prompting a re-evaluation of long-term treatment paradigms, safety profiles, and cost-effectiveness. Consequently, stakeholders require a clear synthesis of evolving evidence to inform strategic planning.

This executive summary delivers a cohesive introduction to the PNH therapeutic arena, framing key developments in complement inhibition, logistical considerations, and patient-centric care. Through an authoritative lens, it sets the stage for deeper analysis, empowering decision-makers to align clinical, regulatory, and commercial initiatives with the current trajectory of PNH treatment development.

Exploration of Transformative Shifts Shaping PNH Management Including Innovation, Policy Changes, and Patient-Centric Care Models Impacting Therapeutic Strategies

The PNH treatment landscape has undergone transformative shifts driven by next-generation therapeutics, evolving regulatory frameworks, and an intensified focus on patient-centered care. In recent years, long-acting C5 inhibitors have extended dosing intervals while novel C3 inhibitors have introduced oral dosing possibilities, fundamentally redefining patient convenience and adherence. Regulatory authorities have adapted approval pathways to accommodate these innovations, often incorporating real-world evidence to streamline reviews and encourage post-market safety monitoring.

In parallel, payers and providers are increasingly embracing value-based pricing agreements that tie reimbursement to clinical outcomes. This shift underscores the rising importance of demonstrating sustained hemolysis control, quality of life improvements, and reduction in thrombotic events. Furthermore, home infusion programs and telemedicine platforms have gained traction, enabling decentralized administration and continuous patient monitoring.

Taken together, these dynamics are reshaping therapeutic strategies and fostering a more nuanced understanding of PNH management. As stakeholders navigate this period of rapid innovation, they must integrate clinical efficacy data with economic and operational considerations to ensure seamless delivery of emerging therapies and optimal patient outcomes.

Comprehensive Analysis of the Cumulative Impact of Anticipated 2025 United States Tariffs on PNH Therapeutics Supply Chains and Market Access

The introduction of new import tariffs slated for 2025 poses a strategic inflection point for PNH therapeutic supply chains in the United States. Manufacturers sourcing critical biologic components and raw materials internationally may encounter increased costs that pressure existing pricing structures. In turn, these cost pressures can influence negotiated reimbursement rates, potentially prompting adjustments in patient co-payment levels or manufacturer discount programs.

Meanwhile, distributors and specialty pharmacies are reassessing logistics models to mitigate tariff-driven expenses. Firms are exploring domestic production of critical excipients, forging partnerships with regional suppliers, and investing in tariff classification expertise to optimize duty payments. These efforts aim to preserve therapy affordability and maintain uninterrupted patient access.

Despite the challenges, proactive handshakes between industry and policy makers have the potential to soften the cumulative impact. Strategic engagement with customs authorities, participation in trade advocacy coalitions, and exploration of preferential trade agreements present viable pathways forward. By aligning tariff mitigation strategies with robust patient support programs, companies can safeguard treatment continuity and uphold the integrity of the PNH care continuum.

Key Segmentation Insights Revealed Through Treatment Types, Mechanism of Action, Administration Routes, End User Dynamics, and Distribution Channels

A granular examination of PNH treatment segmentation offers critical insights into competitive dynamics and patient experience. By treatment type, established complement blockade is represented by Eculizumab while Pegcetacoplan brings targeted C3 inhibition to the forefront, and Ravulizumab extends the C5 inhibition paradigm with prolonged dosing intervals. Each modality delivers unique pharmacokinetic properties, administration burdens, and safety profiles that inform clinical decision-making.

An assessment of the mechanism of action reveals that C3 inhibitors intercept proximal complement activation, delivering comprehensive hemolysis prevention at the expense of broader immune modulation, whereas C5 inhibitors focus on terminal blockade to reduce breakthrough hemolysis events. These mechanistic distinctions influence real-world tolerability, monitoring requirements, and long-term safety considerations.

Route of administration further differentiates patient pathways, as intravenous infusions demand specialized clinical settings, subcutaneous injections enable broader self-administration, and emerging oral options promise maximal convenience yet require robust absorption and metabolism profiling. End user dynamics reinforce these variations, with home care settings offering personalized support, hospitals ensuring intensive monitoring, and specialty clinics balancing procedural expertise with patient throughput.

Distribution channels also play a pivotal role: hospital pharmacies coordinate inpatient access, online pharmacies facilitate direct-to-patient delivery, and retail pharmacies integrate community-based dispensing. Together, these layered segments define the real-world landscape in which PNH therapies compete, collaborate, and evolve.

Strategic Regional Insights Mapping the PNH Therapeutic Landscape Across the Americas, Europe Middle East Africa, and the Asia-Pacific Markets

Regional nuances exert a profound influence on PNH treatment access, administration, and healthcare economics. In the Americas, robust reimbursement frameworks support broad uptake of biologics, while advanced specialty pharmacy networks and patient assistance programs help mitigate financial barriers. Urban centers in North America and select Latin American markets benefit from integrated care models that accelerate therapy initiation and monitoring.

In Europe, the Middle East, and Africa, heterogeneous regulatory landscapes and pricing pressures demand adaptable launch strategies. Western European countries employ health technology assessments that prioritize cost-effectiveness metrics, whereas Middle Eastern health authorities are forging public-private partnerships to expand orphan disease treatment capacity. Sub-Saharan Africa remains challenged by infrastructure gaps, yet pilot programs in specialty centers are laying the groundwork for future expansions.

In the Asia-Pacific region, Japan and Australia lead in early adoption of next-generation complement inhibitors, supported by robust clinical trial ecosystems and favorable reimbursement policies. Mainland China has steadily improved rare disease coverage through innovative insurance schemes, while Southeast Asian countries continue to invest in specialty care centers to bridge urban-rural treatment divides. Collectively, these regions illustrate the importance of tailored regulatory engagement and localized access initiatives.

In-Depth Analysis of Leading Companies Driving Innovation in PNH Treatment Including Pipeline Progress, Collaborations, and Strategic Positioning

Industry leadership in the PNH arena is characterized by the pioneering efforts of established biopharmaceutical companies alongside agile biotechnology firms. One leading organization has solidified its position by advancing the complement C5 inhibition platform through lifecycle management and expanded indication pursuits. Concurrently, an emerging biotech innovator has disrupted the landscape with the first proximal C3 inhibitor, securing global partnerships to accelerate late-stage clinical development.

Collaborative ventures between large pharmaceutical players and niche specialists are accelerating manufacturing scale-up, ensuring consistent supply of complex biologics. These alliances also facilitate knowledge transfer in areas such as subcutaneous delivery device creation and real-world evidence generation. In parallel, several companies have invested heavily in patient support ecosystems, offering digital adherence tools, virtual nursing services, and financial assistance initiatives that enhance therapy uptake and persistence.

As competition intensifies, leading organizations increasingly differentiate through pipeline diversification that spans gene therapy explorations, novel antibody constructs, and immunomodulatory adjuncts. The interplay of strategic acquisitions, co-development agreements, and targeted licensing deals underscores the importance of flexible business models to capture value in this dynamic landscape.

Actionable Recommendations for Industry Leaders to Capitalize on Emerging Opportunities in PNH Therapeutics and Strengthen Market Positioning

Industry leaders must adopt decisive strategies to capitalize on emerging PNH therapeutic opportunities. First, directing research investments toward oral and long-acting modalities will address unmet patient needs for convenience and adherence. Simultaneously, early engagement with payers through value demonstration studies will facilitate favorable coverage terms.

Operationally, strengthening supply chain resilience by diversifying raw material sourcing and establishing regional manufacturing hubs can mitigate tariff and logistical uncertainties. Complementing these efforts with advanced demand forecasting and cold-chain analytics will further optimize distribution efficiency.

On the commercial front, embedding digital patient support platforms and telemedicine integration will enhance treatment initiation and long-term follow-up. Partnering with specialist networks and home care providers can broaden access beyond traditional infusion centers. Moreover, leveraging real-world data to quantify quality of life improvements and long-term safety outcomes will reinforce value-based contracting discussions.

Finally, cultivating collaborative partnerships across industry, regulatory bodies, and patient advocacy groups will foster an ecosystem that supports accelerated innovation, equitable access, and sustainable growth within the PNH therapeutic space.

Comprehensive Research Methodology Detailing Data Sources, Expert Validation Processes, and Analytical Frameworks Underpinning the PNH Treatment Study

The research underpinning this PNH treatment analysis integrates primary and secondary methodologies to ensure robust, validated insights. Primary research included structured interviews with hematology opinion leaders, payers, specialty pharmacy directors, and regulatory experts. These discussions provided qualitative perspectives on therapeutic adoption, reimbursement landscapes, and clinical unmet needs.

Secondary research encompassed comprehensive reviews of peer-reviewed publications, clinical trial registries, patent landscapes, regulatory filings, and treatment guidelines. Analysts performed data triangulation by cross-referencing public company disclosures, real-world evidence databases, and health technology assessment reports.

An expert panel convened to vet preliminary findings, refine thematic interpretations, and validate strategic implications. Quantitative analysis employed statistical techniques to identify trends in clinical outcomes, dosing patterns, and service utilization without extrapolating market forecasts. All research protocols adhered to ethical guidelines and employed transparent documentation practices to ensure reproducibility and credibility.

Conclusive Perspectives Summarizing Critical Findings, Future Outlook, and the Strategic Imperatives for Stakeholders in the PNH Therapeutic Arena

This analysis distills critical insights into the evolving PNH therapeutic landscape, emphasizing the confluence of novel modalities, regulatory adaptations, and patient-centric models. The anticipated tariff changes in 2025 underscore the necessity for supply chain agility and proactive stakeholder collaboration. Segmentation nuances across treatment types, mechanisms of action, administration routes, end user environments, and distribution channels highlight the multilayered complexity shaping therapy adoption.

Regional perspectives from the Americas, Europe Middle East Africa, and Asia-Pacific underscore the imperative of localized strategies that align with heterogeneous reimbursement and regulatory paradigms. Company-level dynamics reveal a competitive ecosystem driven by pipeline innovation, strategic alliances, and patient support program excellence.

Collectively, these findings illuminate a path forward in which industry leaders can harness actionable recommendations to optimize therapeutic access, strengthen value demonstration, and enhance patient outcomes. This conclusion serves as a foundation for informed decision-making, enabling stakeholders to navigate the transformative era of PNH treatment with clarity and confidence.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Treatment Type
    • Eculizumab
    • Pegcetacoplan
    • Ravulizumab
  • Mechanism Of Action
    • C3 Inhibitor
    • C5 Inhibitor
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • End User
    • Home Care Settings
    • Hospitals
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • Alexion Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals, Inc.
  • Swedish Orphan Biovitrum AB (publ)

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Real-world evidence analysis of long-term safety profiles of complement inhibitors in PNH patients
5.2. Comparative efficacy outcomes of novel C3 inhibitors versus eculizumab in PNH management
5.3. Impact of oral C5 inhibitor formulations on treatment adherence and patient quality of life in PNH
5.4. Emerging gene therapy approaches targeting PIGA mutations for potential curative interventions in PNH
5.5. Pharmacoeconomic assessments of next-generation complement inhibitors highlighting cost-effectiveness in PNH
5.6. Subcutaneous ravulizumab dosing frequency innovations and their implications for healthcare resource utilization in PNH
5.7. Regulatory pathway evolutions influencing accelerated approval and reimbursement of PNH therapies globally
5.8. Integration of biomarkers and personalized medicine strategies to optimize treatment selection in PNH management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Treatment of PNH Market, by Treatment Type
8.1. Introduction
8.2. Eculizumab
8.3. Pegcetacoplan
8.4. Ravulizumab
9. Treatment of PNH Market, by Mechanism Of Action
9.1. Introduction
9.2. C3 Inhibitor
9.3. C5 Inhibitor
10. Treatment of PNH Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Treatment of PNH Market, by End User
11.1. Introduction
11.2. Home Care Settings
11.3. Hospitals
11.4. Specialty Clinics
12. Treatment of PNH Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Treatment of PNH Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Treatment of PNH Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Treatment of PNH Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Alexion Pharmaceuticals, Inc.
16.3.2. Apellis Pharmaceuticals, Inc.
16.3.3. Swedish Orphan Biovitrum AB (publ)
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. TREATMENT OF PNH MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL TREATMENT OF PNH MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL TREATMENT OF PNH MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TREATMENT OF PNH MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TREATMENT OF PNH MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. TREATMENT OF PNH MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. TREATMENT OF PNH MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. TREATMENT OF PNH MARKET: RESEARCHAI
FIGURE 26. TREATMENT OF PNH MARKET: RESEARCHSTATISTICS
FIGURE 27. TREATMENT OF PNH MARKET: RESEARCHCONTACTS
FIGURE 28. TREATMENT OF PNH MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. TREATMENT OF PNH MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TREATMENT OF PNH MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL TREATMENT OF PNH MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL TREATMENT OF PNH MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL TREATMENT OF PNH MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ECULIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL TREATMENT OF PNH MARKET SIZE, BY PEGCETACOPLAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL TREATMENT OF PNH MARKET SIZE, BY PEGCETACOPLAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL TREATMENT OF PNH MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL TREATMENT OF PNH MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C3 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C3 INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C5 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL TREATMENT OF PNH MARKET SIZE, BY C5 INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL TREATMENT OF PNH MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL TREATMENT OF PNH MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL TREATMENT OF PNH MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL TREATMENT OF PNH MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL TREATMENT OF PNH MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL TREATMENT OF PNH MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL TREATMENT OF PNH MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES TREATMENT OF PNH MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 71. CANADA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 72. CANADA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 73. CANADA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 74. CANADA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 75. CANADA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 76. CANADA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 77. CANADA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. CANADA TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. CANADA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. CANADA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. MEXICO TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 82. MEXICO TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 83. MEXICO TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 84. MEXICO TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 85. MEXICO TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 86. MEXICO TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 87. MEXICO TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. MEXICO TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. MEXICO TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. MEXICO TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. BRAZIL TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. BRAZIL TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 107. ARGENTINA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. ARGENTINA TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. ARGENTINA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. ARGENTINA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF PNH MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. UNITED KINGDOM TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. UNITED KINGDOM TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. UNITED KINGDOM TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. GERMANY TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 134. GERMANY TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 135. GERMANY TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 136. GERMANY TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 137. GERMANY TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. GERMANY TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. GERMANY TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. GERMANY TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. GERMANY TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. GERMANY TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. FRANCE TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 144. FRANCE TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 145. FRANCE TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 146. FRANCE TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 147. FRANCE TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. FRANCE TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. FRANCE TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. FRANCE TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. FRANCE TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. FRANCE TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 155. RUSSIA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 156. RUSSIA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 157. RUSSIA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. RUSSIA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. RUSSIA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. RUSSIA TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. RUSSIA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. RUSSIA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. ITALY TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 164. ITALY TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 165. ITALY TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 166. ITALY TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 167. ITALY TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 168. ITALY TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 169. ITALY TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. ITALY TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. ITALY TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. ITALY TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. SPAIN TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 174. SPAIN TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 175. SPAIN TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 176. SPAIN TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 177. SPAIN TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. SPAIN TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. SPAIN TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. SPAIN TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. SPAIN TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. SPAIN TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 196. SAUDI ARABIA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. SAUDI ARABIA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. SAUDI ARABIA TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. SAUDI ARABIA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 206. SOUTH AFRICA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. SOUTH AFRICA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. SOUTH AFRICA TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. SOUTH AFRICA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. DENMARK TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 214. DENMARK TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 215. DENMARK TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 216. DENMARK TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 217. DENMARK TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. DENMARK TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. DENMARK TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. DENMARK TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. DENMARK TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. DENMARK TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 225. NETHERLANDS TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 226. NETHERLANDS TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 227. NETHERLANDS TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. NETHERLANDS TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. NETHERLANDS TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. NETHERLANDS TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. NETHERLANDS TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. NETHERLANDS TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. QATAR TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 234. QATAR TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 235. QATAR TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 236. QATAR TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 237. QATAR TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. QATAR TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. QATAR TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. QATAR TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. QATAR TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. QATAR TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. FINLAND TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 244. FINLAND TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 245. FINLAND TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 246. FINLAND TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 247. FINLAND TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. FINLAND TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. FINLAND TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. FINLAND TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. FINLAND TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. FINLAND TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 255. SWEDEN TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 256. SWEDEN TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 257. SWEDEN TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. SWEDEN TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. SWEDEN TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. SWEDEN TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. SWEDEN TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. SWEDEN TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 265. NIGERIA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 266. NIGERIA TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 267. NIGERIA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. NIGERIA TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. NIGERIA TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. NIGERIA TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. NIGERIA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. NIGERIA TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. EGYPT TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 274. EGYPT TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 275. EGYPT TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 276. EGYPT TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 277. EGYPT TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 278. EGYPT TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 279. EGYPT TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. EGYPT TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. EGYPT TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. EGYPT TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. TURKEY TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 284. TURKEY TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 285. TURKEY TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 286. TURKEY TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 287. TURKEY TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. TURKEY TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. TURKEY TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. TURKEY TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. TURKEY TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. TURKEY TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. ISRAEL TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 294. ISRAEL TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 295. ISRAEL TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 296. ISRAEL TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 297. ISRAEL TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 298. ISRAEL TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 299. ISRAEL TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. ISRAEL TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. ISRAEL TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. ISRAEL TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. NORWAY TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 304. NORWAY TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 305. NORWAY TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 306. NORWAY TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 307. NORWAY TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 308. NORWAY TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 309. NORWAY TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. NORWAY TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. NORWAY TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 312. NORWAY TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 313. POLAND TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 314. POLAND TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 315. POLAND TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 316. POLAND TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 317. POLAND TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 318. POLAND TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 319. POLAND TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 320. POLAND TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 321. POLAND TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 322. POLAND TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 323. SWITZERLAND TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 324. SWITZERLAND TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 325. SWITZERLAND TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 326. SWITZERLAND TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 327. SWITZERLAND TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 328. SWITZERLAND TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 329. SWITZERLAND TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 330. SWITZERLAND TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 331. SWITZERLAND TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 332. SWITZERLAND TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 333. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 334. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 335. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 336. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 337. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 338. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 339. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 340. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 341. ASIA-PACIFIC TREATMENT OF PNH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 342. ASIA-PACIFIC

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Treatment of PNH market report include:
  • Alexion Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals, Inc.
  • Swedish Orphan Biovitrum AB (publ)

Related Reports

Drugs for PNH Market by Drug Class (Proximal Complement Inhibitors, Terminal Complement Inhibitors), Route of Administration (Intravenous, Subcutaneous), Distribution Channel, End User, Line of Therapy, Age Group - Global Forecast 2025-2030 - Product Image

Drugs for PNH Market by Drug Class (Proximal Complement Inhibitors, Terminal Complement Inhibitors), Route of Administration (Intravenous, Subcutaneous), Distribution Channel, End User, Line of Therapy, Age Group - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Strategic Business Report - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Strategic Business Report

  • Report
  • 126 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Report 2025 - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Global Market Report 2025 - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Paroxysmal Nocturnal Haemoglobinuria - Pipeline Insight, 2025 - Product Image

Paroxysmal Nocturnal Haemoglobinuria - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.